HCA shares fall as investors weigh workforce cuts and cost outlook ahead of conference appearance

HCA Healthcare (HCA) is down 3.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The decline looks tied to renewed investor focus on cost and staffing actions after reports that HCA made non-clinical workforce reductions, with some traders also positioning ahead of management’s scheduled healthcare-conference presentation. The move may also reflect lingering sensitivity after the company’s recent quarterly update, when labor and supply-cost commentary has been a key swing factor for hospital operators.

Details:

HCA confirmed an undisclosed number of non-clinical layoffs, describing the cuts as a “small portion” of its workforce and noting it continues to hire across a wide range of roles.

HCA is scheduled to present at RBC Capital Markets’ Global Healthcare Conference on May 20, 2026, which can prompt short-term repositioning into or out of the event.

In late April, HCA’s quarterly results drew attention to expense discipline, and the stock has remained reactive to any incremental signals on labor and supply trends.

An April 2026 SEC filing detailed a senior-notes offering and planned redemptions of near-term notes, highlighting ongoing balance-sheet and refinancing activity.

Sources:

Fierce Healthcare, HCA Healthcare Investor Relations, U.S. SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HCA Insider Trading Activity

$HCA insiders have traded $HCA stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.

Here’s a breakdown of recent trading of $HCA stock by insiders over the last 6 months:

SAMUEL N HAZEN (CEO) has made 0 purchases and 7 sales selling 42,877 shares for an estimated $21,483,274.
JENNIFER BERRES (SVP & Chief Human Res. Officer) has made 0 purchases and 2 sales selling 8,020 shares for an estimated $4,126,950.
CHRISTOPHER F. WYATT (SVP & Controller) sold 4,000 shares for an estimated $2,020,000
MICHAEL R MCALEVEY (EVP & Chief Legal & Admin Off.) sold 1,694 shares for an estimated $903,536
MICHAEL S. CUFFE (EVP and Chief Clinical Officer) sold 1,500 shares for an estimated $747,135

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive HCA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$HCA Hedge Fund Activity

We have seen 609 institutional investors add shares of $HCA stock to their portfolio, and 730 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL INTERNATIONAL INVESTORS added 3,033,612 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,435,626,542
CAPITAL WORLD INVESTORS removed 3,026,993 shares (-60.5%) from their portfolio in Q1 2026, for an estimated $1,432,494,167
SANDERS CAPITAL, LLC removed 1,507,023 shares (-14.4%) from their portfolio in Q1 2026, for an estimated $713,183,564
PACER ADVISORS, INC. removed 911,096 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $425,354,278
BLACKROCK, INC. added 782,179 shares (+6.2%) to their portfolio in Q1 2026, for an estimated $370,158,389
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 647,721 shares (-97.6%) from their portfolio in Q1 2026, for an estimated $306,527,486
JPMORGAN CHASE & CO removed 627,849 shares (-21.0%) from their portfolio in Q4 2025, for an estimated $293,117,584

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$HCA Analyst Ratings

Wall Street analysts have issued reports on $HCA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Oppenheimer issued a "Outperform" rating on 01/28/2026
Truist Securities issued a "Buy" rating on 01/28/2026
Deutsche Bank issued a "Buy" rating on 01/28/2026
Barclays issued a "Overweight" rating on 01/28/2026
Jefferies issued a "Buy" rating on 01/28/2026
Morgan Stanley issued a "Underweight" rating on 12/15/2025

To track analyst ratings and price targets for $HCA, check out Quiver Quantitative's $HCA forecast page.

$HCA Price Targets

Multiple analysts have issued price targets for $HCA recently. We have seen 16 analysts offer price targets for $HCA in the last 6 months, with a median target of $534.5.

Here are some recent targets:

David Macdonald from Truist Securities set a target price of $535.0 on 04/27/2026
Matthew Gillmor from Keybanc set a target price of $510.0 on 04/27/2026
Michael Wiederhorn from Oppenheimer set a target price of $520.0 on 04/27/2026
Andrew Mok from Barclays set a target price of $496.0 on 04/27/2026
Ben Hendrix from RBC Capital set a target price of $534.0 on 04/27/2026
Stephen Baxter from Wells Fargo set a target price of $436.0 on 04/27/2026
Raj Kumar from Stephens & Co. set a target price of $530.0 on 04/27/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.